JPS649289B2 - - Google Patents

Info

Publication number
JPS649289B2
JPS649289B2 JP54011717A JP1171779A JPS649289B2 JP S649289 B2 JPS649289 B2 JP S649289B2 JP 54011717 A JP54011717 A JP 54011717A JP 1171779 A JP1171779 A JP 1171779A JP S649289 B2 JPS649289 B2 JP S649289B2
Authority
JP
Japan
Prior art keywords
carnitine
acetyl
acyl derivatives
hyperlipidemia
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP54011717A
Other languages
English (en)
Japanese (ja)
Other versions
JPS54113442A (en
Inventor
Kabaza Kuraujio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT4790078A external-priority patent/IT1104165B/it
Priority claimed from IT4935478A external-priority patent/IT1156740B/it
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of JPS54113442A publication Critical patent/JPS54113442A/ja
Publication of JPS649289B2 publication Critical patent/JPS649289B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP1171779A 1978-02-03 1979-02-03 Treating agent of hyperlipoid disease Granted JPS54113442A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT4790078A IT1104165B (it) 1978-02-03 1978-02-03 Nuova applicazione terapeutica della carnitina della acetil-carnitina e di altri derivati acilati della carnitina
IT4935478A IT1156740B (it) 1978-05-15 1978-05-15 Applicazione terapeutica della acetil-carnitina e di altri derivati acilati della carnitina

Publications (2)

Publication Number Publication Date
JPS54113442A JPS54113442A (en) 1979-09-05
JPS649289B2 true JPS649289B2 (Direct) 1989-02-16

Family

ID=26329245

Family Applications (1)

Application Number Title Priority Date Filing Date
JP1171779A Granted JPS54113442A (en) 1978-02-03 1979-02-03 Treating agent of hyperlipoid disease

Country Status (6)

Country Link
US (1) US4268524A (Direct)
JP (1) JPS54113442A (Direct)
CH (1) CH640413A5 (Direct)
DE (1) DE2903579A1 (Direct)
GB (1) GB2013496B (Direct)
NL (1) NL7900872A (Direct)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1156741B (it) * 1978-05-15 1987-02-04 Sigma Tau Ind Farmaceuti Applicazione terapeutica della carnitina e di alcuni derivati acilati della carnitina nell'emodialisi
IT1206954B (it) * 1979-02-12 1989-05-17 Sigma Tau Ind Farmaceuti Agenti terapeutici a base di un acil derivato della carnitina per la cura di vasculopatie periferiche
IT1116037B (it) * 1979-04-23 1986-02-10 Sigma Tau Ind Farmaceuti Esteri e ammidi di acil carnitine loro procedimenti di preparazione e loro uso terapeutico
IT1145362B (it) * 1980-03-06 1986-11-05 Sigma Tau Ind Farmaceuti Classe di acil-derivati della carnitina procedimento per la loro preparazione e loro uso terapeutico
IT1143214B (it) * 1981-07-09 1986-10-22 Sigma Tau Ind Farmaceuti Acil derivato della carnitina quale immunomodulatore
IT1150751B (it) * 1982-04-01 1986-12-17 Montedison Spa Composizioni acaricide
IT1157238B (it) * 1982-10-29 1987-02-11 Sigma Tau Ind Farmaceuti Impiego di 1-carnitina per migliorare i paramenti biochimici e comportamentali dell'eta' senile
FR2619007B1 (fr) * 1987-08-07 1990-09-28 Dermatologiques Et Preparations cosmetiques a action lipolytique
FR2633929B2 (fr) * 1987-09-25 1995-05-24 Picardie Universite Derives non toxiques de l'acide n-butyrique, presentant des actions therapeutiques retardees
IT1224842B (it) * 1988-12-27 1990-10-24 Sigma Tau Ind Farmaceuti Uso di derivati della l-carnitina nel trattamento terapeutico delle alterazioni degenerative del sistema nervoso
IT1231944B (it) * 1989-05-05 1992-01-16 Sigma Tau Ind Farmaceuti Composizione farmaceutica per il trattamento di protozoosi, particolarmente della tripasonomiasi comprendente d-carnitina o un alcanoilderivato della d-carnitina
FR2654619B1 (fr) * 1989-11-23 1992-01-31 Sederma Sa Utilisation en cosmetique de composes destines a optimiser la penetration des principes actifs.
IT1248321B (it) * 1991-05-15 1995-01-05 Sigma Tau Ind Farmaceuti Uso di esteri di acil l-carnitine con l'acido gamma-idrossibutirrico per produrre composizioni farmaceutiche per il trattamento di epatopatie
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6129930A (en) * 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6080428A (en) * 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US20060263428A1 (en) * 1993-09-20 2006-11-23 Eugenio Cefali Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
IT1276253B1 (it) 1995-12-15 1997-10-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o alcanoil l-carnitine per la prevenzione ed il trattamento di stati morbosi
IT1293067B1 (it) * 1997-07-01 1999-02-11 Sigma Tau Ind Farmaceuti Composizione farmaceutica per il trattamento di patologie causate da alterato metabolismo lipidico
ITRM20010708A1 (it) * 2001-12-04 2003-06-04 Sigma Tau Ind Farmaceuti Uso di una alcanoil l-carnitina per il trattamento della disfunzione erettile.
DE10331202A1 (de) 2003-07-10 2005-03-31 S.K. Enterprise Gmbh Verwendung von Molkenpermeat zur Behandlung des Metabolischen Syndroms
US8173618B2 (en) * 2003-07-25 2012-05-08 University Of Massachusetts Formulations for reducing neuronal degeneration
ITRM20040307A1 (it) 2004-06-23 2004-09-23 Sigma Tau Ind Farmaceuti Confezione per almeno due prodotti differenti da vendere e utilizzare insieme.
JP2006347935A (ja) * 2005-06-15 2006-12-28 Masanori Ogata 炎症性サイトカインの産生が関与する疾患の予防及び／又は治療のための医薬
EP1957066A4 (en) 2005-11-11 2013-08-28 V Ravi Chandran ACETYLATED AMINO ACIDS AS A THROMBOZYTE AGGREGATION INHIBITOR, FOOD AND VITAMIN SUPPLEMENT
DE102006036285A1 (de) 2006-08-03 2008-02-07 "S.U.K." Beteiligungs Gmbh Fraktionen aus Molkepermeat und deren Verwendung zur Prävention und Therapie des Typ-2 Diabetes und des Metabolischen Syndroms
US8597640B2 (en) * 2007-10-31 2013-12-03 University Of Massachusetts Lowell Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3810994A (en) * 1972-06-01 1974-05-14 Ethyl Corp Method and composition for treating obesity
US3968241A (en) * 1972-11-06 1976-07-06 Defelice Stephen L Method of treating cardiac arrhythmias and of improving myocardial contractility and systolic rhythm with carnitive or a pharmaceutically acceptable salt thereof
US4032641A (en) * 1976-06-09 1977-06-28 Tanabe Seiyaku Co., Ltd. Nicotinoyl carnitine derivatives
AU518617B2 (en) * 1977-04-29 1981-10-08 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Therapeutic application of acetyl-d, 1-carnitine
IT1143611B (it) * 1977-11-03 1986-10-22 Sigma Tau Ind Farmaceuti Applicazione della acetil-carnitina nella terapia delle affezioni cardiache di/tipo anossico,ischemico,cardiotossico e nelle sindromi aritmiche

Also Published As

Publication number Publication date
DE2903579A1 (de) 1979-08-09
GB2013496A (en) 1979-08-15
JPS54113442A (en) 1979-09-05
NL7900872A (nl) 1979-08-07
US4268524A (en) 1981-05-19
GB2013496B (en) 1983-01-12
CH640413A5 (it) 1984-01-13

Similar Documents

Publication Publication Date Title
JPS649289B2 (Direct)
JPS649287B2 (Direct)
US4194006A (en) Therapeutic application of acetyl-d,l-carnitine and other acyl derivatives of d,l-carnitine
US5157022A (en) Method for reducing blood cholesterol using arginine
US4613593A (en) Therapeutic and preventive agent containing dolichol
US4100161A (en) Promotion of protein synthesis and suppression of urea formation in the body by keto analogs of essential amino acids
US5227518A (en) L-carnitine derivatives as therapeutical agents for treating myopathies and neuronal degeneration and for inhibiting proteolysis
JPS5843996A (ja) 安定なｓ−アデノシルメチオニン塩、それらの製造法及び活性成分としてこれらを含む治療組成物
US10751310B2 (en) Prevention, treatment and reversal of disease using therapeutically effective amounts of dicarboxylic acid compounds
NL8200022A (nl) Farmaceutische samenstelling, die gamma-butyrobetaine bevat, voor de behandeling van door l-carnitine gebrek teweeggebrachte syndromen.
EP0204989A2 (de) Verwendung von Penicillamin zur Behandlung von Immunmangelkrankheiten
DE3726945A1 (de) L-carnitinderivate der valproinsaeure und diese enthaltende arzneimittel
US4315944A (en) Pharmaceutical composition comprising L-carnitine for the treatment of hyperlipidaemias and hyperlipoproteinaemias
US4237165A (en) Treatment of carbohydrate metabolism disorders
EP0225856B1 (en) Use of acetyl l-carnitine for the preparation of a medicament for the therapeutical treatment of shock conditions
US4474812A (en) Pharmaceutical composition for improving the biochemical and behavioral parameters of senility
JPS62190190A (ja) Ｌ−カルニチンのホスホリルアルカノ−ルアミド誘導体類およびその医薬組成物
US4148920A (en) Therapeutic L- and DL- phenylglycines to treat diseases or disorders of reduced blood flow or oxygen availability
CA1136551A (en) Composition containing acetyl carnitine and other acyl derivatives of carnitine for treating hyperlipoproteinaemias and hyperlipidaemias
US4791105A (en) Therapeutic and preventive agent containing dolichol
US4603126A (en) Therapeutic and preventive agent containing dolichol
EP0149847A2 (en) Therapeutic and preventive agent containing dolichol
FR2515962A1 (fr) Preparations medicamenteuses contenant un derive d'acide tetraiodothyrocarboxylique notamment pour le traitement de l'hypercholesterolemie
EP1547614B1 (en) Medicinal composition for inhibiting the expression of atp-citrate lyase and use thereof
US4599328A (en) Therapeutic and preventive agent containing dolichol